Chronic Lymphocytic Leukemia

Article

Chronic lymphocytic leukemia (also called CLL) is a blood and bone marrow Hutchinson Center research related to Chronic Lymphocytic

Chronic Lymphocytic Leukemia News

Gemin X Biotechnologies Initiates Phase 1/2 Clinical Trial with GX15-070 in Chronic Lymphocytic Leukemia; FDA Grants Orphan Drug Designation for GX15-070 in CLL.

MONTREAL - Gemin X Biotechnologies Inc. announced today the initiation of a Phase 1/2 clinical trial in chronic lymphocytic leukemia (CLL) with GX15-070, a novel, targeted cancer treatment that is designed to induce apoptosis (natural cell death) by inhibiting the Bcl-2 family of proteins, one of

KineMed Reports Data Demonstrating New Insights into the Cellular Progression of Chronic Lymphocytic Leukemia ; Results Could Alter How CLL is Treated in the Future.

EMERYVILLE, Calif., March 1 /PRNewswire/ - KineMed, Inc., a platform- based drug development and advanced medical diagnostics company, today announced the publication of data in the March 1 print issue, February 10 online issue, of the Journal of Clinical Investigation demonstrating new insights

Memorial Sloan-Kettering Cancer Center Phase I/II Study Concludes SuperGen's Pentostatin , in Combination Therapy, Shows 'Excellent Activity and Tolerability' in Chronic Lymphocytic Leukemia .

Data presented at Innovative Cancer Therapy for Tomorrow symposium co-sponsored by Mount Sinai School of Medicine and The Chemotherapy Foundation DUBLIN, Calif., Nov. 13 /PRNewswire/ - SuperGen Inc. (Nasdaq: SUPG) announced today that data from a phase I/II study of its anticancer drug pentostatin

Gemin X Biotechnologies Initiates Phase 1/2 Clinical Trial with GX15- 070 in Chronic Lymphocytic Leukemia; FDA Grants Orphan Drug Designation for GX15-070 in CLL

MONTREALCCNMatthews - Jan 6, 2005) - Gemin X Biotechnologies Inc. announced today the initiation of a Phase 1/2 clinical trial in chronic lymphocytic leukemia (CLL) with GX15-070, a novel, targeted cancer treatment that is designed to induce apoptosis (natural cell death) by inhibiting the Bcl-2

Chronic Lymphocytic Leukemia - CLL - Patients Reach Five-Year Survival Milestone After Receiving Campath Therapy.

Chronic Lymphocytic Leukemia (CLL) is the most prevalent form of adult leukemia. According to a recent study, 84 percent of patients with CLL in whom all detectable traces of the disease were eliminated were still alive at least five years after receiving Campath (alemtuzumab) therapy. The study